Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stok Raporu

Piyasa değeri: US$502.7m

Olema Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 3/4

Olema Pharmaceuticals CEO'su Sean Bohen, Sep2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 3.15M olup, şirket hissesi ve opsiyonları dahil olmak üzere 20.5% maaş ve 79.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.25% ine doğrudan sahiptir ve bu hisseler $ 1.27M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 4.3 yıldır.

Anahtar bilgiler

Sean Bohen

İcra Kurulu Başkanı

US$3.2m

Toplam tazminat

CEO maaş yüzdesi20.5%
CEO görev süresi4.2yrs
CEO sahipliği0.3%
Yönetim ortalama görev süresi3.5yrs
Yönetim Kurulu ortalama görev süresi4.3yrs

Son yönetim güncellemeleri

Recent updates

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Aug 29
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Olema Pharmaceuticals: Still Merits A Small Holding

Jun 17

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

May 11
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Palazestrant's Journey: Olema Pharmaceuticals' Long Oncology Path

Mar 28

Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Mar 04
Estimating The Fair Value Of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Situation

We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Jun 11
We're Keeping An Eye On Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Mar 01
Will Olema Pharmaceuticals (NASDAQ:OLMA) Spend Its Cash Wisely?

Olema Oncology grants stock options for 58.3K shares

Oct 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 13
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Olema Pharmaceuticals GAAP EPS of -$0.82 misses by $0.18

Aug 09

Olema stock soars 12% as FDA grants fast track status to OP-1250 for breast cancer subtype

Jul 21

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

May 29
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Easily Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 08
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Our Take On Olema Pharmaceuticals

Jan 05

We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

Sep 19
We're Not Very Worried About Olema Pharmaceuticals' (NASDAQ:OLMA) Cash Burn Rate

We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Jun 04
We Think Olema Pharmaceuticals (NASDAQ:OLMA) Can Afford To Drive Business Growth

Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

Feb 19
Companies Like Olema Pharmaceuticals (NASDAQ:OLMA) Are In A Position To Invest In Growth

CEO Tazminat Analizi

Sean Bohen'un ücretlendirmesi Olema Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$123m

Jun 30 2024n/an/a

-US$110m

Mar 31 2024n/an/a

-US$99m

Dec 31 2023US$3mUS$647k

-US$97m

Sep 30 2023n/an/a

-US$96m

Jun 30 2023n/an/a

-US$97m

Mar 31 2023n/an/a

-US$110m

Dec 31 2022US$6mUS$616k

-US$105m

Sep 30 2022n/an/a

-US$100m

Jun 30 2022n/an/a

-US$95m

Mar 31 2022n/an/a

-US$79m

Dec 31 2021US$3mUS$595k

-US$71m

Sep 30 2021n/an/a

-US$60m

Jun 30 2021n/an/a

-US$52m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$11mUS$178k

-US$24m

Tazminat ve Piyasa: Sean 'nin toplam tazminatı ($USD 3.15M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.14M ).

Tazminat ve Kazançlar: Sean 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Sean Bohen (57 yo)

4.2yrs

Görev süresi

US$3,152,370

Tazminat

Dr. Sean P. Bohen, M.D., Ph.D. has been a Director at AltruBio, Inc. He is the Chief Executive Officer and Director of Olema Pharmaceuticals, Inc. since September 2020 and serves as its President. He serve...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sean Bohen
President4.2yrsUS$3.15m0.25%
$ 1.3m
Shane William Kovacs
Chief Operating & Financial Officer4.4yrsUS$1.55m0.89%
$ 4.5m
Naseem Zojwalla
Chief Medical Officer2.8yrsUS$1.30m0.16%
$ 788.7k
Courtney O'Konek
Vice President of Corporate Communicationsless than a yearVeri yokVeri yok
Julie Dexter
Senior VP & Head of Peopleno dataVeri yokVeri yok
David Myles
Chief Discovery & Non-Clinical Development Officer4.4yrsUS$200.00k1.3%
$ 6.5m
Sasha Austin
VP of Finance & Controller1.8yrsVeri yokVeri yok

3.5yrs

Ortalama Görev Süresi

54yo

Ortalama Yaş

Deneyimli Yönetim: OLMA 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sean Bohen
President4.2yrsUS$3.15m0.25%
$ 1.3m
Andrew Rappaport
Independent Director11.8yrsUS$176.65k0.67%
$ 3.4m
Cynthia Butitta
Independent Director4.3yrsUS$180.15k0.15%
$ 736.4k
Ian T. Clark
Independent Chairperson of the Board4.3yrsUS$198.65k0%
$ 0
Frank McCormick
Chairman of Scientific Advisory Board3.6yrsUS$11.81kVeri yok
Pamela M. Klein
Member of Scientific Advisory Boardno dataVeri yokVeri yok
Sandra Horning
Independent Director4yrsUS$158.15k0%
$ 0
Scott Garland
Independent Director1.1yrsUS$280.21k0%
$ 0
Graham L. Walmsley
Independent Director4.7yrsUS$171.15k0%
$ 0
Yi Larson
Independent Director3.6yrsUS$163.15k0%
$ 0
Gorjan Hrustanovic
Independent Director6.3yrsUS$165.15k0%
$ 0
Cyrus Harmon
Director18.3yrsUS$1.33m1.53%
$ 7.7m

4.3yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: OLMA 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).